Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
Delayed Quote. Delayed Nyse - 12/13 04:02:18 pm
87.84 USD   -1.00%
09:37aABBVIE : Form 8.3 -
DJ
12/12ABBVIE : Form 8.3 -AbbVie Inc
DJ
12/12ABBVIE : Form 8.3 -AbbVie Inc
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Upcoming events on ABBVIE
01/14/20 Ex-dividend day for
01/26/20 FY 2019 Earnings Release (Projected)
04/23/20 Q1 2020 Earnings Release (Projected)
07/24/20 Interim 2020 Earnings Release (Projected)
Past events on ABBVIE
12/09/19 | 06:30pm American Society of Hematology Meeting - Phase 1/2 Study Evaluating
12/09/19 | 06:15pm American Society of Hematology Meeting - Refractory Multiple Myeloma
12/09/19 | 03:45pm American Society of Hematology Meeting - Abstract No - 761
12/09/19 | 11:30am American Society of Hematology Meeting - Secondary Myelofibrosis
Upcoming sector events for ABBVIE
12/13/19 UCB SA : Kepler Cheuvreux Conference - One on One
12/13/19 MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN : Roadshow
12/13/19 | 08:00am ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract P4-10-23
12/14/19 | 08:00am ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract P6-13-01
More events
Past sector events for ABBVIE
12/11/19 | 06:00pm ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract P1-18-01
12/12/19 | 06:00pm ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract P3-14-01
12/12/19 | 06:00pm ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract PD7-05
12/12/19 | 06:00pm ROCHE HOLDING AG : San Antonio Breast Cancer Symposium - Abstract OT2-02-06
Annual publications
Annual results2016201720182019 (e)2020 (e)2021 (e)
Sales
M $		 Released
Forecast
Spread		25 560
25 693
-0,52%		28 216
28 011
0,73%		32 733
32 714
0,06%
33 293

37 423

40 277
Operating income
(EBITDA)
M $		 Released
Forecast
Spread		11 830
11 479
3,1%		12 452
12 514
-0,49%		16 358
15 640
4,6%
16 748

19 623

20 929
Operating profit
(EBIT)
M $		 Released
Forecast
Spread		11 405
10 853
5,1%		12 027
11 982
0,37%		14 593
14 695
-0,69%
15 768

18 062

19 637
Pre-Tax Profit
(EBT)
M $		 Released
Forecast
Spread		7 884
7 817
0,85%		7 727
8 862
-13%		5 197
10 814
-52%
12 085




Net income
M $		 Released
Forecast
Spread		5 953
6 145
-3,1%		5 309
7 099
-25%		5 687
10 124
-44%
8 578

11 908

13 108
EPS
 $		 Released
Forecast
Spread		3,63
3,77
-3,8%		3,30
4,41
-25%		3,66
6,50
-44%
5,97

8,59

9,37
Announcement Date01/27/201701/26/201801/25/2019

Assessed data source
© 2019 S&P Global Market Intelligence
© 2019 Factset
Analysis
AstraZeneca shares rise on early U.S. approval for leukaemia drug
Net sales (Year) - Rate of surprise
Operating profit (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Categories
Free services
Mobile App
Premium service
About
Stock Market Quotes Interactive brokers Offre Binck Best of des tweets Stock Market News Börse: Aktien, Kurse und Nachrichten
Copyright © 2019 Surperformance. All rights reserved. Market data are provided by Factset, Morningstar and vwd Group